F-Prime's Ben Aus­pitz co-leads $30M Se­ries A with Or­biMed for his lat­est rare dis­ease ven­ture

Hav­ing spent his 13 years at F-Prime Part­ners back­ing and ad­vis­ing rare dis­ease com­pa­nies — in­clud­ing Di­men­sion Ther­a­peu­tics and Or­chard Ther­a­peu­tics, which he co-found­ed — Ben Aus­pitz is in the game again with a brand new biotech start­up.

Co-lead­ing a $30 mil­lion Se­ries A round for Modis Ther­a­peu­tics with Or­biMed, Aus­pitz is jump­ing in as board chair­man. As for the CEO post, F-Prime has tapped one of its en­tre­pre­neurs-in-res­i­dence, Joshua Grass, who’s al­so a 15-year BD vet­er­an at Bio­Marin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER